Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
2.0
Journals
Children
Special Issues
Children with Leukemia and Lymphoma: Diagnosis and Management
share announcement

Children with Leukemia and Lymphoma: Diagnosis and Management

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Hematology & Oncology".

Deadline for manuscript submissions: closed (25 December 2024) | Viewed by 4195

Special Issue Editors

Dr. Anish K. Ray

E-Mail Website
Guest Editor
Cook Children's Hospital, Fort Worth, TX, USA
Interests: pediatric leukemia; lymphoma; precision medicine; histiocytic disorders (LCH, HLH, and others)
Dr. Kenneth M Heym

E-Mail Website
Guest Editor
Cook Children's Medical Center, Fort Worth, TX, USA
Interests: pediatric leukemia and lymphoma

Special Issue Information

Dear Colleagues,

The cure rate of children with acute leukemias and lymphomas has been a tremendous success with long-term survival approaching 100% for some patients in recent clinical trials; however, survivors face a significant healthcare burden from the current approach that relies heavily on dose-intensified conventional chemotherapy. In recent years, following the boom of artificial intelligence, precision medicine has driven tremendous enthusiasm and interest among patients and providers alike, making it possible to tailor treatment based on driver mutations.

Considering the success of such approaches in select groups of patients, I am now accepting manuscript submissions for a Special Issue in the journal Children (Impact Factor: 2.835).  I invite you to publish your pediatric leukemia and lymphoma research findings and/or reviews of the literature in this Special Issue focusing on “Children with Leukemia and Lymphoma: Diagnosis and Management” for the continuous advancement of outcomes for pediatric leukemia and lymphoma patients.

Dr. Anish K. Ray
Dr. Kenneth M Heym
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric acute lymphoblastic leukemia
  • pediatric acute myeloid leukemia
  • pediatric chronic myeloid leukemia
  • pediatric Hodgkin lymphoma
  • Pediatric non-Hodgkin lymphoma
  • precision medicine in pediatric leukemia and lymphoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1340 KiB  
Article
The Effects of Pediatric Acute Lymphoblastic Leukemia Treatment on Cardiac Repolarization
by Diana R. Lazar, Simona Cainap, Florin Leontin Lazar, Dana Maniu, Cristina Blag, Madalina Bota, Marius C. Colceriu and Mihnea Zdrenghea
Children 2024, 11(10), 1158; https://doi.org/10.3390/children11101158 - 24 Sep 2024
Cited by 1 | Viewed by 1195
Abstract
Background: In recent years, cardiac dysfunction in childhood cancer survivors has become an important issue. Studies are focusing on identifying means for the early identification of patients at risk. Considering this, our study aims to investigate 24-hour Holter electrocardiogram (ECG) repolarization changes [...] Read more.
Background: In recent years, cardiac dysfunction in childhood cancer survivors has become an important issue. Studies are focusing on identifying means for the early identification of patients at risk. Considering this, our study aims to investigate 24-hour Holter electrocardiogram (ECG) repolarization changes throughout doxorubicin (DOX) and cyclophosphamide (CPM) administration in pediatric patients treated for acute lymphoblastic leukemia (ALL). Methods: This was an investigator-driven, single-center, prospective, observational study. Enrolled children had a baseline bedside ECG examination performed before starting chemotherapy (T0). Serial Holter ECG examinations were conducted at three moments during their treatment protocol: day 8 (T1), day 29 (T2), and day 36 (T3). This study evaluated several ECG repolarization parameters, such as the QT interval, corrected QT interval (QTc), and QTc dispersion, as well as ST segment variations. Results: We evaluated 37 children diagnosed with ALL. The T0 examination revealed that over a third of patients had a resting heart rate (HR) outside the normal range for their age and sex. During chemotherapy, statistically significant increases in both HR as well as QT and QTc dispersion values were noticed, especially during the first DOX administration. What is more, a significant increase in the percentage of patients with ST segment depression from T1 to T2 and T3 was noticed. Rhythm disturbances were rare in the study population, with only a few patients presenting ventricular or supraventricular extrasystoles. Conclusions: This study reveals silent repolarization changes occurring early during anticancer treatment in children treated for ALL. These findings could aid in a better understanding of the cardiac toxicity mechanism, and they could potentially improve cardiac risk stratification for oncologic patients. Because of the small number of patients, our results need to be validated by larger studies. Full article
(This article belongs to the Special Issue Children with Leukemia and Lymphoma: Diagnosis and Management)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1683 KiB  
Review
Microbiome Modulation in Pediatric Leukemia: Impact on Graft-Versus-Host Disease and Treatment Outcomes: A Narrative Review
by Samuel Bogdan Todor and Cristian Ichim
Children 2025, 12(2), 166; https://doi.org/10.3390/children12020166 - 29 Jan 2025
Viewed by 904
Abstract
The gut microbiome significantly influences the outcomes of pediatric leukemia, particularly in patients undergoing hematopoietic stem cell transplantation (HSCT). Dysbiosis, caused by chemotherapy, antibiotics, and immune system changes, contributes to complications such as graft-versus-host disease (GVHD), gastrointestinal issues, and infections. Various microbiome-related interventions, [...] Read more.
The gut microbiome significantly influences the outcomes of pediatric leukemia, particularly in patients undergoing hematopoietic stem cell transplantation (HSCT). Dysbiosis, caused by chemotherapy, antibiotics, and immune system changes, contributes to complications such as graft-versus-host disease (GVHD), gastrointestinal issues, and infections. Various microbiome-related interventions, including prebiotics, probiotics, postbiotics, and fecal microbiota transplantation (FMT), have shown potential in mitigating these complications. Specific microbial signatures have been linked to GVHD risk, and interventions like inulin, Lactobacillus, and SCFAs (short-chain fatty acids), particularly butyrate, may help modulate the immune system and improve outcomes. FMT, while showing promising results in restoring microbial balance and alleviating GVHD, still requires careful monitoring due to potential risks in immunocompromised patients. Despite positive findings, more research is needed to optimize microbiome-based therapies and ensure their safety and efficacy in pediatric leukemia care. Full article
(This article belongs to the Special Issue Children with Leukemia and Lymphoma: Diagnosis and Management)
►▼ Show Figures

Figure 1

9 pages, 208 KiB  
Review
Precision Medicine for Acute Lymphoblastic Leukemia in Children: A Review
by Anish Ray, Michael Levitt, Toluwalope Efunkoya and Heidi Trinkman
Children 2024, 11(11), 1329; https://doi.org/10.3390/children11111329 - 30 Oct 2024
Viewed by 1699
Abstract
The clinical outcome for children diagnosed with acute lymphoblastic leukemia is a testimony to the success of modern medicine. Over the past few decades, survival has climbed from ∼10% to >90% for certain subgroups. Yet, the outcome for those with relapsed disease is [...] Read more.
The clinical outcome for children diagnosed with acute lymphoblastic leukemia is a testimony to the success of modern medicine. Over the past few decades, survival has climbed from ∼10% to >90% for certain subgroups. Yet, the outcome for those with relapsed disease is often poor, and survivors struggle with a multitude of healthcare issues, some of which are lifelong. In recent years, the advent of the widespread sequencing of tumors has made available patients with previously unrecognized subtypes of leukemia, who have the potential to benefit from the addition of targeted therapies. Indeed, the promise of precision medicine, encompassing a person’s environment, genetics and lifestyle, is likely to have profound impact on further tailoring therapies that are likely to improve outcomes, diminish toxicity and ultimately pave the pathway for a healthier population. Full article
(This article belongs to the Special Issue Children with Leukemia and Lymphoma: Diagnosis and Management)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop